Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1964 3
1966 1
1967 1
1969 1
1970 3
1971 3
1972 3
1973 3
1974 7
1975 9
1976 6
1977 5
1978 7
1979 3
1980 6
1981 9
1982 12
1983 11
1984 15
1985 16
1986 11
1987 20
1988 22
1989 22
1990 29
1991 23
1992 19
1993 17
1994 21
1995 13
1996 16
1997 21
1998 17
1999 16
2000 13
2001 25
2002 27
2003 30
2004 29
2005 35
2006 30
2007 30
2008 43
2009 37
2010 47
2011 58
2012 72
2013 79
2014 89
2015 83
2016 73
2017 74
2018 81
2019 89
2020 93
2021 103
2022 97
2023 7
Text availability
Article attribute
Article type
Publication date

Search Results

1,576 results
Results by year
Filters applied: . Clear all
Page 1
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. Shore ND, et al. Among authors: george dj. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469183 Clinical Trial.
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Gillessen S, et al. Among authors: george d. Eur Urol. 2022 Jul;82(1):115-141. doi: 10.1016/j.eururo.2022.04.002. Epub 2022 Apr 18. Eur Urol. 2022. PMID: 35450732 Free article.
Proteomic and phosphoproteomic landscapes of acute myeloid leukemia.
Kramer MH, Zhang Q, Sprung R, Day RB, Erdmann-Gilmore P, Li Y, Xu Z, Helton NM, George DR, Mi Y, Westervelt P, Payton JE, Ramakrishnan SM, Miller CA, Link DC, DiPersio JF, Walter MJ, Townsend RR, Ley TJ. Kramer MH, et al. Among authors: george dr. Blood. 2022 Sep 29;140(13):1533-1548. doi: 10.1182/blood.2022016033. Blood. 2022. PMID: 35895896 Free PMC article.
From the Editors.
Hausman BL, George DR. Hausman BL, et al. Among authors: george dr. J Med Humanit. 2022 Sep;43(3):385-386. doi: 10.1007/s10912-022-09746-1. J Med Humanit. 2022. PMID: 35969336 No abstract available.
From the Editors.
Hausman BL, George DR. Hausman BL, et al. Among authors: george dr. J Med Humanit. 2022 Jun;43(2):205. doi: 10.1007/s10912-022-09737-2. J Med Humanit. 2022. PMID: 35507212 No abstract available.
From the Editors.
Hausman BL, George DR. Hausman BL, et al. Among authors: george dr. J Med Humanit. 2022 Mar;43(1):1-2. doi: 10.1007/s10912-022-09731-8. J Med Humanit. 2022. PMID: 35099682 No abstract available.
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Choueiri TK, et al. Among authors: george d. Eur J Cancer. 2018 May;94:115-125. doi: 10.1016/j.ejca.2018.02.012. Epub 2018 Mar 20. Eur J Cancer. 2018. PMID: 29550566 Free PMC article. Clinical Trial.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K; GALAHAD investigators. Smith MR, et al. Among authors: george dj. Lancet Oncol. 2022 Mar;23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9. Epub 2022 Feb 4. Lancet Oncol. 2022. PMID: 35131040 Clinical Trial.
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN Jr. Pal SK, et al. Among authors: george dj. Lancet. 2021 Feb 20;397(10275):695-703. doi: 10.1016/S0140-6736(21)00152-5. Epub 2021 Feb 13. Lancet. 2021. PMID: 33592176 Free PMC article. Clinical Trial.
1,576 results